Abstract 4136741: Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Lipid Reduction: A Network Meta-Analysis

可欣 前蛋白转化酶 枯草杆菌素 医学 PCSK9 还原(数学) 荟萃分析 内科学 药理学 胆固醇 生物化学 低密度脂蛋白受体 脂蛋白 化学 几何学 数学
作者
Hua Shen,Meng Chai,Yujie Zhou
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:150 (Suppl_1)
标识
DOI:10.1161/circ.150.suppl_1.4136741
摘要

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer additional lipid reduction beyond that achieved with statins. However, the optimal PCSK9 therapy for lowering lipid levels in patients with hypercholesterolemia and/or hyperlipidemia on background statin therapy remains unclear. Methods: PubMed and EMBASE databases were searched for RCTs assessing tafolecimab, evolocumab or alirocumab vs. placebo (administrated Q2W or Q4W, 12-week treatment) in patients with hypercholesterolemia and/or hyperlipidemia on medium-intensity statin up to March 28, 2024. The outcomes of interest were the percentage change in low-density lipoprotein cholesterol (LDL-C) or lipoprotein(a) from baseline to the 12th week. A frequentist random-effect network meta-analysis was applied to calculate MD and 95% CI using Stata 16.0 software. Results: A total of 4960 patients [PCSK9 inhibitors (n=3230), placebo (n=1730)] across 13 RCTs were included. At week 12, tafolecimab, evolocumab and alirocumab (either Q2W or Q4W) all induced significant reductions in LDL-C levels compared to placebo ( Figure ). The efficacy of evolocumab Q2W was significantly higher compared with alirocumab Q2W (MD=-18.67%, 95% Cl [-29.59%, -7.74%]), while similar LDL-C reduction was observed in tafolecimab Q2W vs. alirocumab Q2W and evolocumab Q2W vs. tafolecimab Q2W. Furthermore, tafolecimab Q4W and evolocumab Q4W were more effective in lowering LDL-C levels compared to alirocumab Q4W (tafolecimab vs. alirocumab: MD=-23.66%, 95% Cl [-32.58%, -14.74%]; evolocumab vs. alirocumab: MD=-25.84%, 95% Cl [-34.21%, -17.46%]), while there was no difference between evolocumab Q4W and tafolecimab Q4W. Lastly, the ranking of the effects for reducing lipoprotein(a) levels was as follows: tafolecimab > evolocumab> alirocumab (either Q2W or Q4W). Conclusions: In patients with hypercholesterolemia and/or hyperlipidemia treated with medium-intensity statins, tafolecimab and evolocumab (either Q2W or Q4W) might be preferred choices for lowering LDL-C. Additionally, tafolecimab (either Q2W or Q4W) appears to be the most effective agent for reducing lipoprotein(a) levels.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yzxzdm发布了新的文献求助20
1秒前
sylinmm完成签到,获得积分10
1秒前
1秒前
1秒前
3秒前
慕青应助典雅闭月采纳,获得10
5秒前
QZ发布了新的文献求助10
5秒前
清晨发布了新的文献求助10
6秒前
云136完成签到,获得积分10
6秒前
科研通AI5应助科研通管家采纳,获得10
9秒前
guo完成签到,获得积分10
9秒前
9秒前
CipherSage应助科研通管家采纳,获得10
9秒前
思源应助科研通管家采纳,获得10
9秒前
桐桐应助科研通管家采纳,获得10
9秒前
大个应助科研通管家采纳,获得10
9秒前
科研通AI5应助科研通管家采纳,获得10
9秒前
10秒前
科研通AI2S应助Grace采纳,获得30
13秒前
13秒前
becl发布了新的文献求助10
14秒前
orixero应助勤劳怜寒采纳,获得20
14秒前
李爱国应助faye采纳,获得10
15秒前
15秒前
16秒前
彩色的捕发布了新的文献求助10
16秒前
17秒前
李健应助结实的小土豆采纳,获得10
19秒前
Lancelot发布了新的文献求助30
19秒前
小救星小杜完成签到,获得积分10
20秒前
21秒前
Orange应助奶油布丁采纳,获得10
23秒前
zzhui发布了新的文献求助200
23秒前
BillowHu发布了新的文献求助10
23秒前
李健应助番茄炒鸡蛋采纳,获得10
25秒前
25秒前
小蘑菇应助朴实如冰采纳,获得10
25秒前
顺心孤云完成签到,获得积分10
26秒前
27秒前
典雅闭月发布了新的文献求助10
27秒前
高分求助中
Les Mantodea de Guyane Insecta, Polyneoptera 2500
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 (PDF!) 1000
Technologies supporting mass customization of apparel: A pilot project 450
A Field Guide to the Amphibians and Reptiles of Madagascar - Frank Glaw and Miguel Vences - 3rd Edition 400
China Gadabouts: New Frontiers of Humanitarian Nursing, 1941–51 400
The Healthy Socialist Life in Maoist China, 1949–1980 400
Walking a Tightrope: Memories of Wu Jieping, Personal Physician to China's Leaders 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3787081
求助须知:如何正确求助?哪些是违规求助? 3332740
关于积分的说明 10257327
捐赠科研通 3048149
什么是DOI,文献DOI怎么找? 1672981
邀请新用户注册赠送积分活动 801549
科研通“疑难数据库(出版商)”最低求助积分说明 760271